Chemical compounds

Maleic Anhydride Market Worth $3.5 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 4, 2020
Chemical compounds, Chemistry, Psychoactive drugs, Maleic anhydride, Organic acid anhydride, Butane, 1,4-Butanediol, Maleic acid

Another major factor contributing to the growth of the maleic anhydride market is rising global demand for UPR and 1,4-BDO.

Key Points: 
  • Another major factor contributing to the growth of the maleic anhydride market is rising global demand for UPR and 1,4-BDO.
  • N-butane-based maleic anhydride to register the highest CAGR in the global maleic anhydride market, between 2019 and 2024
    The maleic anhydride market is segmented by raw material into n-butane and benzene.
  • N-butane is the widely used raw material and witnesses the highest CAGR in the global maleic anhydride market.
  • APAC is the largest of maleic anhydride market and is expected to witness the highest CAGR between 2019 and 2024.

Maleic Anhydride Market Worth $3.5 Billion by 2024 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, March 4, 2020
Chemical compounds, Chemistry, Psychoactive drugs, Maleic anhydride, Organic acid anhydride, Butane, 1,4-Butanediol, Maleic acid

Another major factor contributing to the growth of the maleic anhydride market is rising global demand for UPR and 1,4-BDO.

Key Points: 
  • Another major factor contributing to the growth of the maleic anhydride market is rising global demand for UPR and 1,4-BDO.
  • N-butane-based maleic anhydride to register the highest CAGR in the global maleic anhydride market, between 2019 and 2024
    The maleic anhydride market is segmented by raw material into n-butane and benzene.
  • N-butane is the widely used raw material and witnesses the highest CAGR in the global maleic anhydride market.
  • APAC is the largest of maleic anhydride market and is expected to witness the highest CAGR between 2019 and 2024.

SIGA Announces Collaboration with Turnstone Biologics

Retrieved on: 
Monday, March 2, 2020
Viruses, Chemical compounds, Medicine, Virotherapy, SIGA Technologies, Oncolytic virus, Tecovirimat, Vaccinia, Turnstone, Immunotherapy

NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX (tecovirimat) in connection with Turnstones proprietary SKV vaccinia oncolytic immunotherapy platform.

Key Points: 
  • NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that it entered into a collaboration with Turnstone Biologics to provide TPOXX (tecovirimat) in connection with Turnstones proprietary SKV vaccinia oncolytic immunotherapy platform.
  • The collaboration will provide Turnstone with access to SIGAs TPOXX oral antiviral capsules for use if required in future clinical programs.
  • TPOXX has potential as a new tool to support the adoption of oncolytic vaccinia virus immunotherapies, including those being developed by Turnstone, said Dr. Phil Gomez, CEO of SIGA.
  • We are pleased to enter into this collaboration with Turnstone Biologics, a leading innovator of next-generation oncolytic viral therapies.

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology

Retrieved on: 
Monday, March 2, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Overactive bladder, RTT, Aromatic compounds, Chemical compounds, Monoclonal antibodies, Medical specialties, Immunosuppressants, Solabegron, Percutaneous tibial nerve stimulation, the Phase 3 Trial, Vibegron, Urovant Sciences

Urovant Sciences (Nasdaq: UROV) announced today the publication of the efficacy and safety results of vibegron in patients with overactive bladder (OAB) from the international Phase 3 EMPOWUR trial.

Key Points: 
  • Urovant Sciences (Nasdaq: UROV) announced today the publication of the efficacy and safety results of vibegron in patients with overactive bladder (OAB) from the international Phase 3 EMPOWUR trial.
  • The peer-reviewed publication is currently available online and the print article is scheduled to be published in the August issue of Journal of Urology.
  • The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.
  • Urovant Sciences reported positive data from the vibegron 12-week, Phase 3 pivotal EMPOWUR study and demonstrated favorable longer-term efficacy, safety, and tolerability in a 40-week extension study.

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer

Retrieved on: 
Monday, March 2, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Chemical compounds, Chemistry, Piperidines, Functional groups, Breakthrough therapy, Protein kinase inhibitors, Lung cancer, Tyrosine kinase receptors, Ceritinib, Pneumonitis, Interstitial lung disease, Anaplastic lymphoma kinase

ALK+ NSCLC is a rarer form of lung cancer, and the needs of people impacted by it are multiple, said Stefania Vallone, President of Lung Cancer Europe (LuCE).

Key Points: 
  • ALK+ NSCLC is a rarer form of lung cancer, and the needs of people impacted by it are multiple, said Stefania Vallone, President of Lung Cancer Europe (LuCE).
  • The positive opinion for ALUNBRIG will now be reviewed by the European Commission (EC) for Commission Decision.
  • Phase 2 ALTA 2, global, single-arm trial evaluating ALUNBRIG in patients with advanced ALK+ NSCLC who have progressed on alectinib or ceritinib.
  • Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ILD)/pneumonitis have occurred with ALUNBRIG.

The Quinism Foundation Calls on GSK to Take Action to Better Emphasize Limitations of Use for Krintafel® (Tafenoquine)

Retrieved on: 
Friday, February 28, 2020
Infectious diseases, Chemical compounds, Quinolines, Medical specialties, RTT, Malaria, Primaquine, Plasmodium vivax, Antimalarial medication, Pamaquine, Tropical diseases, 8-Aminoquinoline

Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."

Key Points: 
  • Consequently, GSK must take appropriate action to better emphasize that approved use of Krintafel is limited to those receiving appropriate antimalarial therapy for acute P. vivax infection and that the drug is NOT indicated for presumptive anti-relapse therapy."
  • [4] "Publicly-available data support a conclusion that tafenoquine shares the liability to CNS neurotoxicity of related 8-aminoquinolines," said Dr. Nevin.
  • Dr. Nevin is a board-certified occupational medicine and preventive medicine physician and former U.S. Army medical officer and epidemiologist.
  • The effects of pentaquine,isopentaquine, primaquine, and pamaquine on the central nervous system of the rhesus monkey.

Are We Doing Enough To Protect Our Hearts?: Millions Of Patients Face Continued Cardiovascular Risk

Retrieved on: 
Friday, February 28, 2020
RTT, Medicine, Health, Chemical compounds, Hepatotoxins, Cardiovascular disease, Statins, Fish oil, Fenofibrate, Niacin, Megavitamin therapy, Hypercholesterolemia

Cardiovascular disease is the number one cause of death for men and women in the United States, accounting for 1 of every 3 deaths.

Key Points: 
  • Cardiovascular disease is the number one cause of death for men and women in the United States, accounting for 1 of every 3 deaths.
  • Statins are the first-line prescription therapy to reduce the risk for cardiovascular events, such as heart attack and stroke, but they only lower the risk of a life-threatening cardiovascular event by 25-35%, which is why many patients turn to or are prescribed additional treatments to further reduce cardiovascular risk.
  • New consumer and physician survey data revealed that patients are often prescribed or recommended fenofibrates, niacin, or dietary fish oil supplements on top of statins to treat their persistent cardiovascular risk.
  • "Treatments to reduce cardiovascular risk are evolving, so it is important that patients and healthcare professionals are aware of and discuss the latest advancements that can protect our hearts."

Global Carbon Dioxide (Liquid, Solid, Gaseous) Industry Analysis & Projections, 2015-2030

Retrieved on: 
Friday, February 28, 2020
Carbon capture and sequestration, Chemical compounds, Chemistry, Climate change, Climate change mitigation, Climate engineering, Carbon dioxide, Greenhouse gases, Carbon capture and storage, Bio-energy with carbon capture and storage, Carbon sequestration

During the historic period, increased demand for oil and gas industry globally contributed to the carbon dioxide market's growth.

Key Points: 
  • During the historic period, increased demand for oil and gas industry globally contributed to the carbon dioxide market's growth.
  • The high cost for capturing, liquefying, and transporting carbon dioxide is a major challenge in the carbon dioxide market.
  • Carbon dioxide manufacturers are using advanced carbon capture and storage (CCS) technologies to effectively capture, purify, liquify, and store carbon dioxide.
  • CCS technologies offers effective method for capturing carbon dioxide, restraining the carbon dioxide from entering the environment.

Global Water Resources Declares Monthly Dividend

Retrieved on: 
Friday, February 28, 2020
Water, Nature, Chemical compounds, Water conservation, Reclaimed water, Sustainable agriculture, Water treatment, Water supply, Water resource management, Water industry

PHOENIX, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), (TSX: GWR), a pure-play water resource management company, has declared, under its dividend policy, a monthly cash dividend in the amount of $0.0241 per common share (an annualized amount of $0.2892 per share), which will be payable on March 31, 2020, to holders of record at the close of business on March 17, 2020.

Key Points: 
  • PHOENIX, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Global Water Resources, Inc. (NASDAQ: GWRS), (TSX: GWR), a pure-play water resource management company, has declared, under its dividend policy, a monthly cash dividend in the amount of $0.0241 per common share (an annualized amount of $0.2892 per share), which will be payable on March 31, 2020, to holders of record at the close of business on March 17, 2020.
  • Global Water Resources, Inc. is a leading water resource management company that owns and operates 12 utilities which provide water, wastewater, and recycled water services.
  • The company has been recognized for its highly-effective implementation of Total Water Management (TWM), an integrated approach to managing the entire water cycle by owning and operating water, wastewater and recycled water utilities within the same geographic area to maximize the beneficial use of recycled water.
  • TWM conserves water by using the right water for the right use and helps protect water supplies in water-scarce areas experiencing population growth.

KemPharm Reports Fourth Quarter and Full-Year 2019 Financial Results

Retrieved on: 
Friday, February 28, 2020
Drugs, Euphoriants, RTT, Morphinans, Psychoactive drugs, Chemical compounds, Hepatotoxins, Hydrocodone, Ketones, Prodrug, Benzhydrocodone, Paracetamol

CELEBRATION, Fla., Feb. 28, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its financial results for the fourth quarter and full-year ended December 31, 2019.

Key Points: 
  • CELEBRATION, Fla., Feb. 28, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today provided an update on the KP415 NDA and reported its financial results for the fourth quarter and full-year ended December 31, 2019.
  • We intend to file as soon as possible and remain on track to submit the NDA this quarter.
  • Net loss for Q4 2019 was driven primarily by an operating loss of $4.4 million and net interest expense and other items of $1.8 million.
  • In addition, KemPharm has received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.